OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis
ABSTRACT: Background: Despite the growing evidence on efficacy, little is known regarding the cost-utility of Vaxom/Imocur (OM-85 BV) supplementation to decrease the probability of recurrent respiratory tract infections in OM-85 BV to reduce the incidence of recurrent respiratory tract infections in...
- Autores:
-
Buendía Rodríguez, Jefferson Antonio
Lindarte Rincón, Erika Fernanda
Guerrero Patiño, Diana
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2022
- Institución:
- Universidad de Antioquia
- Repositorio:
- Repositorio UdeA
- Idioma:
- eng
- OAI Identifier:
- oai:bibliotecadigital.udea.edu.co:10495/45374
- Acceso en línea:
- https://hdl.handle.net/10495/45374
- Palabra clave:
- Niño
Child
Colombia
Análisis Costo-Beneficio
Cost-Benefit Analysis
Infecciones del Tracto Respiratorio
Respiratory Tract Infections
Economía y Organizaciones para la Atención de la Salud
Health Care Economics and Organizations
Corticoesteroides
Adrenal Cortex Hormones
https://id.nlm.nih.gov/mesh/D002648
https://id.nlm.nih.gov/mesh/D003105
https://id.nlm.nih.gov/mesh/D003362
http://id.nlm.nih.gov/mesh/D012141
https://id.nlm.nih.gov/mesh/D004472
https://id.nlm.nih.gov/mesh/D000305
- Rights
- openAccess
- License
- http://creativecommons.org/licenses/by/2.5/co/
| id |
UDEA2_883bfd9f67254dc837aee5d2210d9267 |
|---|---|
| oai_identifier_str |
oai:bibliotecadigital.udea.edu.co:10495/45374 |
| network_acronym_str |
UDEA2 |
| network_name_str |
Repositorio UdeA |
| repository_id_str |
|
| dc.title.spa.fl_str_mv |
OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis |
| title |
OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis |
| spellingShingle |
OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis Niño Child Colombia Análisis Costo-Beneficio Cost-Benefit Analysis Infecciones del Tracto Respiratorio Respiratory Tract Infections Economía y Organizaciones para la Atención de la Salud Health Care Economics and Organizations Corticoesteroides Adrenal Cortex Hormones https://id.nlm.nih.gov/mesh/D002648 https://id.nlm.nih.gov/mesh/D003105 https://id.nlm.nih.gov/mesh/D003362 http://id.nlm.nih.gov/mesh/D012141 https://id.nlm.nih.gov/mesh/D004472 https://id.nlm.nih.gov/mesh/D000305 |
| title_short |
OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis |
| title_full |
OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis |
| title_fullStr |
OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis |
| title_full_unstemmed |
OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis |
| title_sort |
OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis |
| dc.creator.fl_str_mv |
Buendía Rodríguez, Jefferson Antonio Lindarte Rincón, Erika Fernanda Guerrero Patiño, Diana |
| dc.contributor.author.none.fl_str_mv |
Buendía Rodríguez, Jefferson Antonio Lindarte Rincón, Erika Fernanda Guerrero Patiño, Diana |
| dc.contributor.researchgroup.spa.fl_str_mv |
Grupo de Investigación en Farmacología y Toxicología |
| dc.subject.decs.none.fl_str_mv |
Niño Child Colombia Análisis Costo-Beneficio Cost-Benefit Analysis Infecciones del Tracto Respiratorio Respiratory Tract Infections Economía y Organizaciones para la Atención de la Salud Health Care Economics and Organizations Corticoesteroides Adrenal Cortex Hormones |
| topic |
Niño Child Colombia Análisis Costo-Beneficio Cost-Benefit Analysis Infecciones del Tracto Respiratorio Respiratory Tract Infections Economía y Organizaciones para la Atención de la Salud Health Care Economics and Organizations Corticoesteroides Adrenal Cortex Hormones https://id.nlm.nih.gov/mesh/D002648 https://id.nlm.nih.gov/mesh/D003105 https://id.nlm.nih.gov/mesh/D003362 http://id.nlm.nih.gov/mesh/D012141 https://id.nlm.nih.gov/mesh/D004472 https://id.nlm.nih.gov/mesh/D000305 |
| dc.subject.meshuri.none.fl_str_mv |
https://id.nlm.nih.gov/mesh/D002648 https://id.nlm.nih.gov/mesh/D003105 https://id.nlm.nih.gov/mesh/D003362 http://id.nlm.nih.gov/mesh/D012141 https://id.nlm.nih.gov/mesh/D004472 https://id.nlm.nih.gov/mesh/D000305 |
| description |
ABSTRACT: Background: Despite the growing evidence on efficacy, little is known regarding the cost-utility of Vaxom/Imocur (OM-85 BV) supplementation to decrease the probability of recurrent respiratory tract infections in OM-85 BV to reduce the incidence of recurrent respiratory tract infections in children. Methods: A decision tree model was used to estimate the cost and quality-adjusted life-years (QALYs) of OM-85 BV in a patient aged 1-6 with a history of recurrent respiratory tract infections. Multiple sensitivity analyses were conducted to evaluate the robustness of the model. Cost-effectiveness was evaluated using the willingness-to-pay defined for Colombia of US$5180 per QALY. The time horizon defined was six months. Costs were estimated from a societal perspective. Results: The expected annual cost per patient with OM-85 BV was US$843 and with placebo was US$1167. The QALYs per person estimated with OM-85 BV was 0.91 and with placebo was 0.89. Conclusion: In conclusion, our study shows that OM-85 BV is a cost-effective strategy to reduce the incidence of recurrent respiratory tract infections in children. Our study provides evidence that should be used by decision-makers to improve clinical practice guidelines. |
| publishDate |
2022 |
| dc.date.issued.none.fl_str_mv |
2022 |
| dc.date.accessioned.none.fl_str_mv |
2025-03-08T03:13:43Z |
| dc.date.available.none.fl_str_mv |
2025-03-08T03:13:43Z |
| dc.type.spa.fl_str_mv |
Artículo de investigación |
| dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| dc.type.redcol.spa.fl_str_mv |
https://purl.org/redcol/resource_type/ART |
| dc.type.coarversion.spa.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
| dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/article |
| dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| format |
http://purl.org/coar/resource_type/c_2df8fbb1 |
| status_str |
publishedVersion |
| dc.identifier.citation.spa.fl_str_mv |
Buendía JA, Patiño DG, Lindarte EF. OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis. BMC Pulm Med. 2022 Dec 6;22(1):465. doi: 10.1186/s12890-022-02264-9. |
| dc.identifier.uri.none.fl_str_mv |
https://hdl.handle.net/10495/45374 |
| dc.identifier.doi.none.fl_str_mv |
10.1186/s12890-022-02264-9 |
| dc.identifier.eissn.none.fl_str_mv |
1756-0500 |
| identifier_str_mv |
Buendía JA, Patiño DG, Lindarte EF. OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis. BMC Pulm Med. 2022 Dec 6;22(1):465. doi: 10.1186/s12890-022-02264-9. 10.1186/s12890-022-02264-9 1756-0500 |
| url |
https://hdl.handle.net/10495/45374 |
| dc.language.iso.spa.fl_str_mv |
eng |
| language |
eng |
| dc.relation.ispartofjournalabbrev.spa.fl_str_mv |
BMC Res. Notes. |
| dc.relation.citationendpage.spa.fl_str_mv |
7 |
| dc.relation.citationissue.spa.fl_str_mv |
1 |
| dc.relation.citationstartpage.spa.fl_str_mv |
1 |
| dc.relation.citationvolume.spa.fl_str_mv |
22 |
| dc.relation.ispartofjournal.spa.fl_str_mv |
BMC Research Notes |
| dc.rights.uri.*.fl_str_mv |
http://creativecommons.org/licenses/by/2.5/co/ |
| dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by/4.0/ |
| dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/openAccess |
| dc.rights.coar.spa.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
| rights_invalid_str_mv |
http://creativecommons.org/licenses/by/2.5/co/ https://creativecommons.org/licenses/by/4.0/ http://purl.org/coar/access_right/c_abf2 |
| eu_rights_str_mv |
openAccess |
| dc.format.extent.spa.fl_str_mv |
7 páginas |
| dc.format.mimetype.spa.fl_str_mv |
application/pdf |
| dc.publisher.spa.fl_str_mv |
BMC (BioMed Central) |
| dc.publisher.place.spa.fl_str_mv |
Londres, Inglaterra |
| institution |
Universidad de Antioquia |
| bitstream.url.fl_str_mv |
https://bibliotecadigital.udea.edu.co/bitstreams/2fb381db-be0e-4717-96a3-23a6bab8358f/download https://bibliotecadigital.udea.edu.co/bitstreams/36bfb0f0-67db-40af-a999-1497abffe103/download https://bibliotecadigital.udea.edu.co/bitstreams/c130c72f-91ea-4aac-affa-1ffe9d137130/download https://bibliotecadigital.udea.edu.co/bitstreams/31d2d933-2617-4134-b14e-e7a5a46fd82a/download https://bibliotecadigital.udea.edu.co/bitstreams/e30010db-373e-4236-a83c-757e119a112b/download |
| bitstream.checksum.fl_str_mv |
78182f92d5e328cb5769daa3c182a2d8 1646d1f6b96dbbbc38035efc9239ac9c 8a4605be74aa9ea9d79846c1fba20a33 f15a58a323f28c2b7994d13e06acdfcd 1f1f02e166e7ad5c28c75f6aa1a87318 |
| bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 |
| repository.name.fl_str_mv |
Repositorio Institucional de la Universidad de Antioquia |
| repository.mail.fl_str_mv |
aplicacionbibliotecadigitalbiblioteca@udea.edu.co |
| _version_ |
1851052336148905984 |
| spelling |
Buendía Rodríguez, Jefferson AntonioLindarte Rincón, Erika FernandaGuerrero Patiño, DianaGrupo de Investigación en Farmacología y Toxicología2025-03-08T03:13:43Z2025-03-08T03:13:43Z2022Buendía JA, Patiño DG, Lindarte EF. OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysis. BMC Pulm Med. 2022 Dec 6;22(1):465. doi: 10.1186/s12890-022-02264-9.https://hdl.handle.net/10495/4537410.1186/s12890-022-02264-91756-0500ABSTRACT: Background: Despite the growing evidence on efficacy, little is known regarding the cost-utility of Vaxom/Imocur (OM-85 BV) supplementation to decrease the probability of recurrent respiratory tract infections in OM-85 BV to reduce the incidence of recurrent respiratory tract infections in children. Methods: A decision tree model was used to estimate the cost and quality-adjusted life-years (QALYs) of OM-85 BV in a patient aged 1-6 with a history of recurrent respiratory tract infections. Multiple sensitivity analyses were conducted to evaluate the robustness of the model. Cost-effectiveness was evaluated using the willingness-to-pay defined for Colombia of US$5180 per QALY. The time horizon defined was six months. Costs were estimated from a societal perspective. Results: The expected annual cost per patient with OM-85 BV was US$843 and with placebo was US$1167. The QALYs per person estimated with OM-85 BV was 0.91 and with placebo was 0.89. Conclusion: In conclusion, our study shows that OM-85 BV is a cost-effective strategy to reduce the incidence of recurrent respiratory tract infections in children. Our study provides evidence that should be used by decision-makers to improve clinical practice guidelines.COL00399027 páginasapplication/pdfengBMC (BioMed Central)Londres, Inglaterrahttp://creativecommons.org/licenses/by/2.5/co/https://creativecommons.org/licenses/by/4.0/info:eu-repo/semantics/openAccesshttp://purl.org/coar/access_right/c_abf2OM-85 BV in pediatric recurrent respiratory tract infections: a cost-utility analysisArtículo de investigaciónhttp://purl.org/coar/resource_type/c_2df8fbb1https://purl.org/redcol/resource_type/ARThttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionNiñoChildColombiaAnálisis Costo-BeneficioCost-Benefit AnalysisInfecciones del Tracto RespiratorioRespiratory Tract InfectionsEconomía y Organizaciones para la Atención de la SaludHealth Care Economics and OrganizationsCorticoesteroidesAdrenal Cortex Hormoneshttps://id.nlm.nih.gov/mesh/D002648https://id.nlm.nih.gov/mesh/D003105https://id.nlm.nih.gov/mesh/D003362http://id.nlm.nih.gov/mesh/D012141https://id.nlm.nih.gov/mesh/D004472https://id.nlm.nih.gov/mesh/D000305BMC Res. Notes.71122BMC Research NotesPublicationORIGINALBuendiaJefferson_2022_OM-85_BV_Pediatric_Recurrent_Respiratory.pdfBuendiaJefferson_2022_OM-85_BV_Pediatric_Recurrent_Respiratory.pdfArtículo de investigaciónapplication/pdf1441132https://bibliotecadigital.udea.edu.co/bitstreams/2fb381db-be0e-4717-96a3-23a6bab8358f/download78182f92d5e328cb5769daa3c182a2d8MD51trueAnonymousREADCC-LICENSElicense_rdflicense_rdfapplication/rdf+xml; charset=utf-8927https://bibliotecadigital.udea.edu.co/bitstreams/36bfb0f0-67db-40af-a999-1497abffe103/download1646d1f6b96dbbbc38035efc9239ac9cMD52falseAnonymousREADLICENSElicense.txtlicense.txttext/plain; charset=utf-81748https://bibliotecadigital.udea.edu.co/bitstreams/c130c72f-91ea-4aac-affa-1ffe9d137130/download8a4605be74aa9ea9d79846c1fba20a33MD53falseAnonymousREADTEXTBuendiaJefferson_2022_OM-85_BV_Pediatric_Recurrent_Respiratory.pdf.txtBuendiaJefferson_2022_OM-85_BV_Pediatric_Recurrent_Respiratory.pdf.txtExtracted texttext/plain26990https://bibliotecadigital.udea.edu.co/bitstreams/31d2d933-2617-4134-b14e-e7a5a46fd82a/downloadf15a58a323f28c2b7994d13e06acdfcdMD54falseAnonymousREADTHUMBNAILBuendiaJefferson_2022_OM-85_BV_Pediatric_Recurrent_Respiratory.pdf.jpgBuendiaJefferson_2022_OM-85_BV_Pediatric_Recurrent_Respiratory.pdf.jpgGenerated Thumbnailimage/jpeg15069https://bibliotecadigital.udea.edu.co/bitstreams/e30010db-373e-4236-a83c-757e119a112b/download1f1f02e166e7ad5c28c75f6aa1a87318MD55falseAnonymousREAD10495/45374oai:bibliotecadigital.udea.edu.co:10495/453742025-03-26 20:47:07.528http://creativecommons.org/licenses/by/2.5/co/open.accesshttps://bibliotecadigital.udea.edu.coRepositorio Institucional de la Universidad de Antioquiaaplicacionbibliotecadigitalbiblioteca@udea.edu.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 |
